Companies › In8bio
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Allogeneic genetically modified gamma-delta T cells Gene-modified gamma-delta T cell therapy | – | Phase 1 | Glioblastoma | Dec 2026 |
| Autologous genetically modified gamma-delta T cells Gene-modified gamma-delta T cell therapy | – | Phase 1 | Glioblastoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05664243 | Autologous genetically modified gamma-delta T cells | Phase 1 | Glioblastoma | Oncology | Dec 2026 |
| NCT05664243 | Allogeneic genetically modified gamma-delta T cells | Phase 1 | Glioblastoma | Oncology | Dec 2026 |
Cash of $14m on 2026-09-30; operating cash outflow about $17m a year; runway about 10 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.